Laura Vilar-Ribó

May 28, 2024 | nature.com | Laura Vilar-Ribó |Judit Cabana-Domínguez |Silvia Alemany |Natalia Llonga |Bru Cormand |Josep Antoni Ramos-Quiroga | +1 more

AbstractSubstance use disorder (SUD) is a global health problem with a significant impact on individuals and society. The presentation of SUD is diverse, involving various substances, ages at onset, comorbid conditions, and disease trajectories. Current treatments for SUD struggle to address this heterogeneity, resulting in high relapse rates.

May 22, 2024 | nature.com | Judit Cabana-Domínguez |María Soler Artigas |Silvia Alemany |Natalia Llonga |Laura Vilar-Ribó

AbstractAttention-deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are strongly associated with educational attainment (EA), but little is known about their genetic relationship with school performance and whether these links are explained, in part, by the genetic liability of EA.

Apr 16, 2024 | nature.com | Sylvanus Toikumo |Benjamin Pham |Travis T. Mallard |John J Meredith |Laura Vilar-Ribó |Emma Johnson | +14 more

AbstractTobacco use disorder (TUD) is the most prevalent substance use disorder in the world. Genetic factors influence smoking behaviours and although strides have been made using genome-wide association studies to identify risk variants, most variants identified have been for nicotine consumption, rather than TUD.

Aug 3, 2023 | nature.com | Judit Cabana-Domínguez |Silvia Alemany |Laura Vilar-Ribó |Ditte Demontis |Anders D. Børglum |Josep Antoni Ramos-Quiroga | +2 more

AbstractAttention deficit/hyperactivity disorder (ADHD) is a highly heritable neurodevelopmental disorder. We performed a transcriptome-wide association study (TWAS) using the latest genome-wide association study (GWAS) meta-analysis, in 38,691 individuals with ADHD and 186,843 controls, and 14 gene-expression reference panels across multiple brain tissues and whole blood.